ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2007
Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned.
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 119 citations in OpenAlex.
- Transarterial chemoembolization is ineffective for neuroendocrine tumors metastatic to the caudate lobe: a single institution review.World journal of surgical oncology · 2015Trial
- Pancreastatin predicts survival in neuroendocrine tumors.Annals of surgical oncology · 2014Trial
- A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.Annals of oncology : official journal of the European Society for Medical Oncology · 2012Trial
- Contemporary Short-Term Outcomes of Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases.Annals of surgical oncology · 2025Article
- Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?Seminars in interventional radiology · 2024Review
- Transcatheter arterial embolization in patients with neuroendocrine neoplasms related to liver metastasis with different blood supplies.Cancer medicine · 2023Article
- Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.Tomography (Ann Arbor, Mich.) · 2023Review
- Review
- Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor.Cancers · 2022Review
- Neuroendocrine liver metastases: a contemporary review of treatment strategies.Hepatobiliary surgery and nutrition · 2020Review
- The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review.Journal of clinical medicine · 2020Review
- Surgical management of pancreatic neuroendocrine liver metastases.Journal of gastrointestinal oncology · 2020Review
- Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions.Current treatment options in oncology · 2020Review
- Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.Journal of clinical medicine · 2019Review
- Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.Endocrine · 2018Article
- Liver transarterial embolizations in metastatic neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2017Review
- The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons.Reviews in endocrine & metabolic disorders · 2017Review
- Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of OOncotarget · 2017Article
- Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.Pancreas · 2017Article
- Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.Expert opinion on pharmacotherapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatic artery chemoembolization (HACE) is a treatment option in the management of metastatic carcinoid. We reviewed our experience to identify potential factors that influence survival.
methodsThe records of 122 patients with metastatic carcinoid tumor undergoing HACE were reviewed. Log-rank analysis and Cox proportional hazards were applied to identify factors predictive of decreased survival.
resultsMedian follow-up after HACE was 21.5 months. Complications occurred in 23% with periprocedural mortality of 5%. Radiographic tumor regression was seen in 82%, with stabilization of disease in 12%. Median duration of CT response was 19 months. Improvement in symptoms occurred in 92% for median duration of 13 months. HACE resulted in complete normalization of serum pancreastatin in 14%, with greater than 20% reduction in another 66%. Median overall survival was 33.3 months after HACE. Only pancreastatin level > or =5,000 pg/ml was associated with decreased survival by multivariate analysis.
conclusionHACE offers symptom palliation and long-term survival in patients with incurable carcinoid metastases. Although safe, it should be approached cautiously in patients with significant tumor burden as evidenced by pancreastatin levels > or =5,000 pg/ml. We do not recommend whole-liver embolization in these patients but prefer a staged approach to each lobe of the liver.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.